Mumps Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Mumps is a contagious disease that leads to painful swelling of the salivary glands. Mumps is caused by a virus. The virus is spread from person to person by respiratory droplets (for example, when you sneeze) or by direct contact with items that have been contaminated with infected saliva. Symptoms include fever, face pain, headache, sore throat, swelling of the temples or jaw, and swelling of the parotid glands. Treatment includes pain relievers (to get relief for symptoms).
The Mumps drugs in development market research report provide comprehensive information on the therapeutics under development for Mumps, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mumps and features dormant and discontinued projects.
Key Routes of Administration in the Mumps Pipeline Products Market
The key route of administration in the Mumps pipeline products market is subcutaneous.
Key Molecule Types in the Mumps Pipeline Products Market
The key molecule types in the Mumps pipeline products market are live attenuated vaccine, vaccine, recombinant vector vaccine, and small molecule.
Mumps Pipeline Products Market Analysis by Molecule Type
For more molecule type insights, download a free report sample
Major Companies in the Mumps Pipeline Products Market
The major companies in the Mumps pipeline products market are Beijing Minhai Biotechnology Co Ltd, Daiichi Sankyo Co Ltd, GlaxoSmithKline Plc, Shanghai King-Cell Biotechnology Co Ltd, Sinovac Biotech Ltd, and Zydus Lifesciences Ltd
Mumps Pipeline Products Market Analysis by Companies
To know more about major companies, download a free report sample
Market Report Overview
Key routes of administration | Subcutaneous |
Key molecule type | Live Attenuated Vaccine, Vaccine, Recombinant Vector Vaccine, and Small Molecule |
Major companies | Beijing Minhai Biotechnology Co Ltd, Daiichi Sankyo Co Ltd, GlaxoSmithKline Plc, Shanghai King-Cell Biotechnology Co Ltd, Sinovac Biotech Ltd, and Zydus Lifesciences Ltd |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Mumps (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Mumps (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Mumps (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Mumps (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Mumps (Infectious Disease)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Mumps (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Mumps (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Daiichi Sankyo Co Ltd
GlaxoSmithKline Plc
Shanghai King-Cell Biotechnology Co Ltd
Sinovac Biotech Ltd
Zydus Lifesciences Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key routes of administration in the Mumps pipeline products market?
The key route of administration in the Mumps pipeline products market is subcutaneous.
-
What are the key molecule types in the Mumps pipeline products market?
The key molecule types in the Mumps pipeline products market are live attenuated vaccine, vaccine, recombinant vector vaccine, and small molecule.
-
Which are the major companies in the Mumps pipeline products market?
The major companies in the Mumps pipeline products market are Beijing Minhai Biotechnology Co Ltd, Daiichi Sankyo Co Ltd, GlaxoSmithKline Plc, Shanghai King-Cell Biotechnology Co Ltd, Sinovac Biotech Ltd, and Zydus Lifesciences Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.